Clinical Trial Update: A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AT13387 alone or with imatinib in gastrointestinal stromal tumor (GIST) has completed safety and efficacy assessments.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• AT13387 (AT13387)
• Imatinib (imatinib)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Gastrointestinal Stromal Tumor (GIST) | Phase 2 | Status: COMPLETED